

## Biographical Details

**Name:** Shomik Sengupta  
**Nationality:** Australian & USA (dual citizenship)  
**Marital Status:** Married with two children

## Chronological Summary

**2006-now** Practicing Urologist, Melbourne  
**2004-6** Uro-Oncology Fellow, Mayo Clinic, Rochester, MN, USA  
**2001-4** Urology Trainee, Royal Australasian College of Surgeons (RACS) /  
Urological Society of Australasia  
**2000** Master of Surgery, University of Melbourne  
**1998-9** General Surgery Trainee, RACS  
**1996** Anatomy Demonstrator, University of Melbourne  
**1994-5, 7** Resident, Royal Melbourne Hospital  
**1988-93** M.B.,B.S, University of Melbourne

## Academic Training & Certification

**2006** Society of Urologic Oncology accredited fellowship, Mayo Clinic, MN, USA  
**2004** Fellowship of the RACS (Urology)  
**2003** TOEFL passed: ECFMG certificate re-validated  
**2001** Master of Surgery, University of Melbourne, Melbourne  
**1998** Early Management of Severe Trauma (EMST/ATLS), RACS, Melbourne  
**1995** USMLE (Steps I & II)  
**1988-93** M.B.,B.S., University of Melbourne, Melbourne  
**1987** V.C.E. (HSC), Melbourne High School, Melbourne

## Clinical Experience

<b>2006-now</b>	Practicing urologist, (offering general, oncologic and laparoscopic urology), East Melbourne, Glen Waverley, Box Hill and Coburg Consultant Urologist (VMO), Austin Health, Heidelberg
<b>2007-10</b>	Consultant Urologist (VMO), Maroondah Hospital, Ringwood
<b>2006-9</b>	Consultant Urologist (VMO), Alfred Hospital, Prahran
<b>2005-6</b>	Uro-Oncology Fellow, Mayo Clinic, Rochester, MN
<b>2001-4</b>	Urology Trainee, Urological Society of Australasia (Vic), Melbourne
<b>1998-9</b>	General Surgery Trainee, RACS (Vic), Melbourne
<b>1996-2000</b>	Emergency & ICU medical officer, John Fawkner Hospital, Coburg
<b>1994-5, 7</b>	Intern & Basic Surgical Trainee, RACS (Vic), Melbourne

## Research Experience

### Current trial involvement:

- Site co-PI (Austin Hospital) & member of TMC for “SORCE”: International multi-centre trial of adjuvant Sorafenib for intermediate-high risk renal cell carcinoma
- Site co-PI (Austin Hospital) for "RAVES": TROG trial of adjuvant vs early salvage radiotherapy for high-risk pathology at radical prostatectomy
- Co-PI for “Chemo and cognition” trial - Latrobe University
- Member, ANZUP Trials group

<b>2009-now:</b>	Honorary visiting researcher, Ludwig Institute for Cancer Research
<b>2004-9:</b>	Candidate for Doctor of Medicine, University of Melbourne, thesis in preparation
<b>2004-5</b>	Research year of Uro-Oncology Fellowship, Mayo Clinic, Rochester, MN
<b>2000</b>	Master of Surgery, University of Melbourne (graduated 2002)
<b>Prior</b>	Clinical projects during training & laboratory-based vacation studentships

## Teaching Experience

- 2008 on** Co-ordinator of SET1 & 2 trainees & Austin Hospital Representative, Training, Assessment & Education committee (Vic) of USANZ
- 2006 on** Involved in supervision of urology trainees, teaching residents, medical students and nurses and continuing education sessions for GPs
- 2004-6** Lecturer, Urology residency program & Convener, monthly GU Tumor Board, Mayo Clinic, Rochester, MN
- 2001** Conjoint Associate lecturer, Dept of Surg, GMCS, University of NSW, Albury
- 2000** Student mentor & Clinical Associate, RMH, Melbourne
- 1997** Visiting Faculty, Stanford University School of Medicine, Stanford, CA
- 1996-2000** Tutor, Trinity College, University of Melbourne, Melbourne
- 1996** Anatomy demonstrator, University of Melbourne, Melbourne

## Professional Affiliations and Activities

- Fellow of the Royal Australasian College of Surgeons, 2004-current
- Member, Urological Society of Australia & New Zealand, 2003-current (Austin Hospital representative on Victorian TA&E committee, 2008-current)
- Member, American Urological Association, 2005-current
- Member, Society of Urologic Oncology, 2005-current (Fellowship representative on Executive Committee, 2005-6)
- Member, Australian Medical Association, 1993-current
- Member, Clinical Oncology Society of Australia, deputy-chair of urogenital subcommittee
- Member, University of Melbourne Medical Society, 1993-current
- Member, Melbourne High School Old Boys Association, 2007-current
- Alfred Hospital representative, SMICS, 2008-9
- Reviewer, Journal of Urology, BJU International, Cancer, Urologic Oncology, Clinical Anatomy
- Advisory Board member, Sanofi-Aventis, 2009-current
- Advisory Board Member, Abbott Australia, 2008-current

## Honours, Prizes and Scholarships

- 2007** AUA/Astellas prize (Best abstract on prostate cancer)
- 2006** Kelalis prize (Best clinical paper), Minnesota Urological Society
- 2005** Kelalis prize (1<sup>st</sup> place), Minnesota Urological Society
- 2004** National Cancer Institute Travel Award  
RACS Traveling Fellowship
- 2002** Sir Edward Hughes Prize for Surgical Research, Cabrini Hospital
- 2001** Harry Ross Prize for Surgical Research, Royal Melbourne Hospital
- 2000** R.C. Bennett Medal, Royal Australasian College of Surgeons (RACS)
- The University of Melbourne Postgraduate Scholarships:**
- The Leslie Eric Paddle Scholarship
  - The Viola Edith Reid Scholarship
  - The Sir Thomas Naughten Fitzgerald Scholarship
  - The RG & AV Meade Scholarship
  - The RJ Fletcher Research Scholarship
- FOMCS Research Scholarship**, Royal Melbourne Hospital
- 1993** Dean's Honours List, M.B., B.S., University of Melbourne
- University of Melbourne prizes:**
- EH Embley Anaesthetics Prize
  - Edgar Rouse Prize in Occupational Medicine
  - UMMS Elective essay prize
- 1988-9** University of Melbourne undergraduate bursaries
- 1987** Melbourne High School Prizes: Chemistry & Computer Science  
Distinction, Westpac Mathematics Competition  
Second Prize, IBM Mathematics Competition
- 1986** Camberwell High School Prize: Year 11  
Prize-winner, Westpac Mathematics Competition
- 1981-5** St. Xavier's School First Prize in General Proficiency, Class V-IX
- 1979** Ghana International School, First Prize, Class 4

## **Publications**

### **Refereed Original Publications**

1. Ischia J, **Sengupta S** and Webb DR, 2010. Surgery Illustrated: Early release of pedicles and posterior development of the "Veil of Aphrodite" in robotic-assisted laparoscopic prostatectomy. *BJU Int*, in press.
2. Mahar P, Corcoran N, Ludlow K and **Sengupta S**, 2010. Prostate specific antigen: useful screening tool or potential liability? *Aust Fam Physician*, in press
3. Majera JS Jr, Leibovich BC, Lohse CM, **Sengupta S**, Cheville JC, Kwon ED and Blute ML, 2008. Association of abnormal pre-operative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. *Urology*, **71**: 278-82.
4. **Sengupta S**, Blute ML, Bagniewski SM, Inman BA, Leibovich BC, Bergstralh EJ, Myers RP and Zincke H, 2008. "Insignificant" prostate cancer treated by radical retropubic prostatectomy has a risk of progression similar to low-risk "significant" prostate cancer. *BJU Int*, **101**: 170-4
5. Schwartz DJ, **Sengupta S**, Hillman DW, Sargent DJ, Cheville JC, Wilson TM, Mynderse LA, Choo R and Davis BJ, 2007. Prediction of radial distance of extraprostatic extension from pretherapy factors. *Int J Radiat Oncol Biol Phys*, **69**: 411-8
6. Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, **Sengupta S**, Dong H, Cheville JC, Lohse CM, Krcio CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL and Kwon ED, 2007. Tumor-infiltrating FoxP3-CD4+CD25+ T-Cells predict poor survival in renal cell carcinoma. *Clin Cancer Res*, **13**: 2075-81
7. Mercader M, **Sengupta S**, Bodner BK, Mannecke RG, Cosar EF, Moser MT, Ballman KV, Wojcik EM and Kwon ED, 2007. Early effects of pharmacological androgen deprivation in human prostate cancer. *BJU Int*, **99**: 60-7
8. Siddiqui SA, Inman BA, **Sengupta S**, Slezak JM, Bergstralh EJ, Leibovich BC, Zincke H, and Blute ML, 2006. Obesity and survival after radical prostatectomy: a 10-year prospective study. *Cancer*, **107**: 521-9
9. **Sengupta S**, Slezak JM, Blute ML, Leibovich BC, Sebo TJ, Myers RP, Cheville JC, Bergstralh EJ and Zincke H, 2006. Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. *Cancer*, **106**: 2630-5
10. Siddiqui SA, **Sengupta S**, Slezak JM, Bergstralh EJ, Zincke H, and Blute ML, 2006. Impact of familial and hereditary prostate cancer on cancer-specific survival after radical retropubic prostatectomy. *J Urol*, **176**: 1118-21
11. **Sengupta S**, Lohse CM, Cheville JC, Zincke H, Myers RP, Riehle DL, Pankratz VS, Blute ML and Sebo TJ, 2006. Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in the prediction of positive surgical margins at radical prostatectomy. *Urol*, **68**: 94-8
12. **Sengupta S**, Christensen CM, Zincke H, Slezak JM, Leibovich BC, Bergstralh EJ, Myers RP and Blute ML, 2006. Detectable Prostate-specific antigen level between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance. *J Urol*, **176**: 559-63
13. **Sengupta S**, Blute ML, Bagniewski SM, Myers RP, Bergstralh EJ, Leibovich BC and Zincke H, 2006. Rising prostate-specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling-time predicts survival. *J Urol*, **175**: 1684-90
14. Thompson RH, Leibovich BC, Webster WS, Kuntz SM, Dong H, Lohse CM, **Sengupta S**, Frank I, Rodeberg DA, Zincke H, Blute ML, Cheville JC and Kwon ED, 2006. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up, *Cancer Res*, **66**: 3381-5
15. Webster WS, Lohse CM, Thompson RH, Dong H, Leibovich BC, **Sengupta S**, Blute ML, Cheville JC and Kwon ED, 2006. Mononuclear cell infiltration in clear cell renal cell carcinoma independently predicts patient survival. *Cancer*, **107**: 46-53
16. Atwell TD, Wass CT, Callstrom MR, Farrell MA and **Sengupta S**, 2006. Delayed hypertension following cryoablation of an adrenal metastasis. *JVIR*, **17**: 573-5
17. **Sengupta S**, Slezak JM, Blute ML and Bergstralh EJ, 2006. A simple graphical method for the estimation of PSADT. *Urol*, **67**: 408-9

18. **Sengupta S**, Siddiqui SA, Slezak JM, Bergstralh EJ, Leibovich BC, Myers RP, Zincke H and Blute ML, 2006. Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. *J Urol*, **175**: 952-7
19. **Sengupta S**, Lohse CM, Cheville JC, Leibovich BC, Thompson RH, Webster WS, Frank I, Zincke H, Blute ML and Kwon ED, 2006. Pre-operative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. *Cancer*, **106**:304-12
20. **Sengupta S**, Cheville JC, Corless CL, Lohse CM, Heinrich MC, Kwon ED, Zincke Z, Blute ML and Leibovich BC, 2006. Rare expression of KIT and absence of *KIT* mutations in high-grade renal cell carcinoma. *J Urol*, **175**: 53-56
21. **Sengupta S**, Myers RP, Slezak JM, Bergstralh EJ, Zincke H and Blute ML, 2005. Pre-operative prostate specific antigen doubling time is a strong and independent predictor of outcomes following radical prostatectomy. *J Urol*, **174**: 2191-6
22. **Sengupta S**, Zincke H and Blute ML, 2005. Re: the accuracy of 250 fine-needle biopsies of renal tumors. *J Urol*, **174**: 2422
23. Thompson H, Webster WS, Cheville JC, Lohse CM, Dong H, Leibovich BC, Kuntz SM, **Sengupta S**, Kwon ED, Blute ML, 2005. B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. *Urol*, **66 (s5)**: 10-4
24. **Sengupta S**, Lohse CM, Leibovich BC, Frank I, Thompson RH, Webster WS, Zincke H, Blute ML, Cheville JC and Kwon ED, 2005. Histological coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. *Cancer*, **104**: 511-20
25. **Sengupta S**, Zincke H, Leibovich BC and Blute ML, 2005. Surgical treatment of stage pt3b renal cell carcinoma in solitary kidneys: a case series. *BJU Int*, **96**: 54-7
26. Katz D, **Sengupta S** and Snow R, 2005. Isolated vasculitis of the bladder. *Urol*, **65**: 797.e8-e10
27. **Sengupta S**, Duncan HJ, Macgregor RJ and Russell JM, 2005. The development of prostate cancer despite late onset androgen deficiency. *Int J Urol*, **12**: 847-8
28. **Sengupta S**, Buchanan M and Danne P, 2005. Malakoplakia of the gall bladder. *Indian J Surg*, **67**: 156-8
29. Wong CSM, **Sengupta S**, Tjandra JJ and Gibson PR, 2005. The influence of specific luminal factors on the colonic epithelium: high dose butyrate and physical changes suppress early carcinogenic events in rats. *Dis Colon Rectum*, **48**: 549-59
30. Thompson H, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, **Sengupta S**, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED, 2004. Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. *Proc Natl Acad Sci USA* **101**: 17174-9
31. **Sengupta S**, Tang CL, Wong CSM, Tjandra JJ and Gibson PR, 2002. Colonic epithelial atrophy induced by a fibre-free diet in rats is reversed by minimal amounts of luminal butyrate, but only in the short-term. *ANZ J Surg* **72**: 871-6
32. Tong R, **Sengupta S** and Tjandra JJ, 2002. Left paraduodenal hernia: a case report and review of the literature. *ANZ J Surg* **72**: 69-71
33. Tang CL, Wong CSM, **Sengupta S**, Tjandra JJ and Gibson PR, 2002. Development of a chronic colonic intubation model in rats for the study of luminal factors in colonic diseases. *Dis Colon Rectum* **45**: 256-63
34. Tjandra JJ and **Sengupta S**, 2001. Argon plasma coagulation is an effective treatment for refractory hemorrhagic radiation proctitis. *Dis Colon Rectum* **44**: 1759-65
35. **Sengupta S** and Webb DR, 2001. Use of a computer-controlled bipolar diathermy system in radical prostatectomies and other open urological surgery. *ANZ J Surg* **71**: 538-40
36. Thomas PR and **Sengupta S**, 2001. Prediction of pancreatitis following endoscopic retrograde cholangiopancreatography by the 4-h post-procedure amylase level. *J Gastroenterol Hepatol*. **16**: 923-6
37. **Sengupta S**, Donnellan S, Vincent JM and Webb DR, 2000. CT analysis of calyceal orientation in the supine and prone position. *J Endourol* **14**: 555-7
38. **Sengupta S** and Crosthwaite G, 2000. Should the one-minute unbuffered urease test be read at ten minutes? *Gut* **47**: 155-6
39. **Sengupta S** and Harewood L, 1998. Transitional cell carcinoma growing along an indwelling nephrostomy tube track. *Br J Urol* **82**: 591
40. Azad AA, Failla P, Lucantoni A, Bentley J, Mardon C, Wolfe A, Fuller K, Hewish D, **Sengupta S**, Sankovich S, Grgacic E, McPhee D and Macreadie I, 1994. Large-scale production and

characterisation of recombinant human immunodeficiency virus type-1 nef. *J Gen Virol* **75**: 651-655

### Invited Reviews, Book Chapters etc.

1. **Sengupta S** and Blute ML, 2008. PSA kinetics in the management of prostate cancer, *J Urol*, **179**: 821-6
2. **Sengupta S** and Blute ML, 2007. Considerations in imaging for Renal Cell Carcinoma. In: de la Rosette J, Manyak M, Harisinghani M and Wijkstra H [eds], *Imaging in Oncologic Urology*. In press
3. Boorjian S, **Sengupta S** and Blute ML, 2007. Renal cell carcinoma with venous tumor thrombus. *BJU Int*, **99**: 1239-44
4. **Sengupta S** and Zincke H, 2006. Practice Point: Is nephron-sparing surgery for small renal masses underused? *Nat Clin Pract Urol*, **3**: 412-3
5. **Sengupta S** and Blute ML, 2006. Predictive models for prostate cancer. *AUA Update Series*, vol **25**: lesson 35
6. **Sengupta S** and Blute ML, 2006. The management of superficial bladder cancer. *Urol*, **67(s1)**: 48-54
7. **Sengupta S**, Muir J and Gibson PR, 2006. Does butyrate protect from colorectal cancer? *J Gastroenterol Hepatol* **21**: 209-18
8. **Sengupta S** and Zincke H, 2005. Practice Point: Is radical prostatectomy of benefit in men with localized prostate cancer? *Nat Clin Pract Oncol*, **2**: 608-9
9. **Sengupta S** and Zincke H, 2005. Lessons learnt in the surgical management of renal cell carcinoma. *Urol*, **66 (s5)**: 36-42
10. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, **Sengupta S**, Chen L, Zincke H, Blute ML, Leibovich BC, Kwon ED, 2005. Aberrant expression of costimulatory B7-H1 in clear cell renal cell carcinoma. *Am J Urol Rev* **3**:244-9
11. **Sengupta S**, Leibovich BC, Blute ML and Zincke H, 2005. Surgery for metastatic renal cell carcinoma – a review. *World J Urol* **23**: 155-60
12. **Sengupta S**, Skandarajah A and Tjandra JJ, 2003. Fibre and colorectal neoplasia – what is the truth? In: Seow-Cheon F (ed). *Topics in Colorectal Cancer*. Stallion Press: London. Chapter 42. pp 328-39
13. **Sengupta S**, 2001. Dose-dependence of the effects of butyrate on the colonic epithelium and tumorigenesis [Master of Surgery Thesis]. University of Melbourne, Melbourne
14. **Sengupta S** and Tjandra JJ, 2001. Current status: local excision of rectal cancer – what is the evidence? *Dis Colon Rectum* **44**: 1345-61
15. **Sengupta S**, Tjandra JJ and Gibson PR, 2001. Current status: fibre and colorectal neoplasia. *Dis Colon Rectum* **44**: 1016-33

### Presentations at International Meetings

- *Annual Scientific Meeting of the Urological Society of Australia and New Zealand*, Gold Coast, March 2009
  - a. **Sengupta S**. Small renal masses: surveillance.
  - b. **Sengupta S**, Ischia J and Webb DR. New technique of urethro-vesical anastomosis during robot-assisted laparoscopic radical prostatectomy. [video].
  - c. **Sengupta S**, Ischia J and Webb DR. Posterior development of the "Veil of Aphrodite" during robot-assisted laparoscopic radical prostatectomy. [video].
- **Sengupta S**, Blute ML, Bagniewski SM, Inman BA, Leibovich BC, Bergstralh EJ, Myers RP and Zincke H. "Insignificant" prostate cancer treated by radical retropubic prostatectomy has a risk of progression similar to low-risk "significant" prostate cancer [poster]. *Annual Meeting of the American Urological Association*, Anaheim, May 2007:
- *Annual Meeting of the American Urological Association*, Atlanta, May 2006:
  - a. **Sengupta S**, Leibovich BC, Corless CL, Cheville JC, Lohse JM, Heinrich MC, Zincke H, Kwon ED, Blute ML. C-Kit protein expression in grade 4 renal cell carcinoma with or without sarcomatoid differentiation [poster].

- b. **Sengupta S**, Christensen CM, Zincke H, Slezak JM, Leibovich BC, Bergstralh EJ, Myers RP and Blute ML. Detectable Prostate-specific antigen level between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance [poster].
- c. **Sengupta S**, Slezak JM, Leibovich BC, Myers RP, Bergstralh EJ, Zincke H, and Blute ML. Primary Gleason grade 4 prostate cancer treated by radical prostatectomy: pathological stage, DNA ploidy and tumor size are more important determinants of survival than secondary Gleason grade [poster].
- **Sengupta S**, Leibovich BC, Corless CL, Cheville JC, Lohse JM, Heinrich MC, Zincke H, Kwon ED, Blute ML. C-Kit protein expression in grade 4 renal cell carcinoma with or without sarcomatoid differentiation [poster]. *6<sup>th</sup> Annual Meeting, Society of Urologic Oncology*, Bethesda, December 2005
- *Annual Meeting of the American Urological Association*, San Antonio, May 2005:
  - a. **Sengupta S**, Slezak JM, Bergstralh EJ, Leibovich BC, Myers RP, Zincke H, Blute ML. Pre-operative PSADT is More Powerful than PSA or PSA Velocity as a Predictor of Post-Radical Prostatectomy Outcomes.
  - b. **Sengupta S**, Lohse CM, Leibovich BC, Frank I, Zincke H, Blute ML, Kwon ED, Cheville JC. Histologic Coagulative Tumor Necrosis: an Important Prognostic Feature of Renal Cell Cancer [poster].
  - c. **Sengupta S**, Lohse CM, Dicks DL, Leibovich BC, Cheville JC, Zincke H, Blute ML, Kwon ED. Erythrocyte Sedimentation Rate: an Independent Prognostic Feature of Clear Cell Renal Cell Cancer [poster].
  - d. **Sengupta S**, Schenk, GS, Slezak JM, Bagniewski SM, Bergstralh EJ, Leibovich BC, Myers RP, Zincke H, Blute ML. PSA Doubling Time is an Important Predictor of Outcomes in Patients with Hormone Refractory Recurrence Following Radical Prostatectomy [poster].
  - e. **Sengupta S**, Slezak JM, Bergstralh EJ, Leibovich BC, Myers RP, Zincke H, Blute ML. Trends in Gleason Grading in Radical Prostatectomy Specimens over Time [poster]. *Annual Meeting of the American Urological Association*, San Antonio, May 2005
- *5<sup>th</sup> Annual Meeting, Society of Urologic Oncology*, Bethesda, December 2004:
  - a. Mercader-Bravo M, **Sengupta S**, Thompson RH, Webster WS, Frigola X, Dong HD, Leibovich BC, Zincke H, Blute ML and Kwon ED. Transitional Cell Carcinoma of the Bladder is Infiltrated by High Proportions of Regulatory T-Lymphocytes.
  - b. **Sengupta S**, Lohse C, Leibovich BC, Frank I, Zincke H, Blute ML, Kwon ED and Cheville JC. Histological Tumor Necrosis as a Prognostic Factor in Renal Cell Carcinoma [poster]. *5<sup>th</sup> Annual Meeting, Society of Urologic Oncology*, Bethesda, December 2004
- **Sengupta S**, Duncan HJ, Macgregor RJ, Russell JM. Audit of a Mobile Regional ESWL Service [Keith Kirkland Presentation]. *Annual Scientific Meeting of the Urological Society of Australasia*, Perth, April 2002
- **Sengupta S**, Wong CSM, Tjandra JJ, Gibson PR. Proof that Butyrate Delivery to the Distal Colon Suppresses Colorectal Tumorigenesis in Rats. *Asia Pacific Digestive Diseases Week*, Sydney, September 2001
- **Sengupta S**, Tjandra JJ, Gibson PR. Fibre and Colorectal Neoplasia: Fact or Myth. *Australasian Gastrointestinal Trials Group 2<sup>nd</sup> Annual Scientific Meeting*, Coolum, August 2000
- **Sengupta S**, Tjandra JJ, Ooi BS, Dwyer P and Carey M. Transanal Repair of Rectocele: 3 Years On. *Royal Australasian College of Surgeons Annual Scientific Congress*, Melbourne, May 2000
- **Sengupta S**, Donnellan S, Vincent JM and Webb DR. CT Analysis of Calyceal Orientation in the Supine and Prone Positions. *51<sup>st</sup> Annual Scientific Meeting of the Urological Society of Australasia*, Melbourne, March 1998

### **Published Abstracts**

1. **Sengupta S**, Ischia J and Webb DR, 2009. New technique of urethro-vesical anastomosis during robot-assisted laparoscopic radical prostatectomy. *BJU Int*: **103 (s1)**, 20 (A061)
2. **Sengupta S**, Ischia J and Webb DR, 2009. Posterior development of the "Veil of Aphrodite" during robot-assisted laparoscopic radical prostatectomy. *BJU Int*: **103 (s1)**, 20 (A062)
3. So D, **Sengupta S**, Royce P and Chang C, 2009. Initial experience of laparoscopic radical prostatectomy at the Alfred Hospital, Melbourne. *BJU Int*: **103 (s1)**, 3 (A012)
4. So D, **Sengupta S**, Chang C and Royce P, 2009. Contemporary evaluation of radical prostatectomy: experience in a single institution. *BJU Int*: **103 (s1)**, 22 (A070)

5. **Sengupta S**, Blute ML, Bagniewski SM, Inman BA, Leibovich BC, Bergstralh EJ, Myers RP, Zincke H, 2007. “Insignificant” prostate cancer treated by radical retropubic prostatectomy has a risk of progression similar to low-risk “significant” prostate cancer [poster]. *J Urol* **177(4s)**: 462 (A1403)
6. **Sengupta S**, Leibovich BC, Corless CL, Cheville JC, Lohse CM, Heinrich MC, Kwon ED, Zincke H, Blute ML, 2006. Rare expression or mutation of c-Kit in grade 4 renal cell carcinoma with or without sarcomatoid differentiation. *J Urol* **175(4s)**: 125 (A383)
7. Webster WS, Dong H, Thompson RH, **Sengupta S**, Lohse CM, Leibovich BC, Blute ML, Kwon ED, 2006. Complete regression of established murine renal cell carcinoma following CD4+ T-cell depletion and B7-H1 blockade. *J Urol* **175(4s)**: 130 (A399)
8. Siddiqui SA, **Sengupta S**, Slezak JM, Leibovich BC, Zincke H, Blute ML, 2006. The long-term impact of obesity on prostate cancer after radical prostatectomy. *J Urol* **175(4s)**: 156 (A482)
9. Webster WS, Lohse CM, Thompson RH, Dong H, Frigola X, Dicks D, **Sengupta S**, Frank I, Leibovich BC, Cheville JC, Blute ML, Kwon ED, 2006. Mononuclear cell infiltrate in clear cell renal cell carcinoma predicts patient survival. *J Urol* **175(4s)**: 242 (A746)
10. **Sengupta S**, Christensen CM, Zincke H, Slezak JM, Leibovich BC, Bergstralh EJ, Myers RP, Blute ML, 2006. Detectable prostate-specific antigen levels between 60 to 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance. *J Urol* **175(4s)**: 276 (A856)
11. Magera JS, Leibovich BC, Lohse CM, **Sengupta S**, Cheville JC, Zincke H, Kwon ED, Blute ML, 2006. Association of abnormal pre-operative laboratory values with survival following radical nephrectomy for clinically confined clear cell renal cell carcinoma. *J Urol* **175(4s)**: 352 (A1095)
12. Magera JS, Leibovich BC, Lohse CM, **Sengupta S**, Cheville JC, Zincke H, Kwon ED, Blute ML, 2006. Association of pre-operative elevated erythrocyte sedimentation rate and anemia with survival following radical nephrectomy for chromophobe, papillary and clear cell renal cell carcinoma. *J Urol* **175(4s)**: 362 (A1127)
13. **Sengupta S**, Leibovich BC, Slezak JM, Myers RP, Bergstralh EJ, Zincke H, Blute ML, 2006. Primary Gleason 4 prostate cancer treated by radical prostatectomy: pathological stage, DNA ploidy and tumor size are stronger determinants of survival than secondary Gleason grade. *J Urol* **175(4s)**: 511 (A1587)
14. **Sengupta S**, Lohse CM, Leibovich BC, Frank I, Zincke H, Blute ML, Kwon ED, Cheville JC, 2005. Histologic Coagulative Tumor Necrosis: an Important Prognostic Feature of Renal Cell Cancer. *J Urol* **173(4s)**: 261 (A963)
15. **Sengupta S**, Lohse CM, Dicks DL, Leibovich BC, Cheville JC, Zincke H, Blute ML, Kwon ED, 2005. Erythrocyte Sedimentation Rate: an Independent Prognostic Feature of Clear Cell Renal Cell Cancer. *J Urol* **173(4s)**: 261 (A965)
16. Siddiqui SA, **Sengupta S**, Slezak JM, Bergstralh EJ, Leibovich BC, Myers RP, Zincke H, Blute ML, 2005. Age at Treatment is not a Good Predictor of Outcomes Following Radical Retropubic Prostatectomy. *J Urol* **173(s4)**: 75 (A271)
17. **Sengupta S**, Slezak JM, Bergstralh EJ, Leibovich BC, Myers RP, Zincke H, Blute ML, 2005. Pre-operative PSADT is More Powerful than PSA or PSA Velocity as a Predictor of Post-Radical Prostatectomy Outcomes. *J Urol* **173(s4)**: 257 (A950)
18. **Sengupta S**, Schenk, GS, Slezak JM, Bagniewski SM, Bergstralh EJ, Leibovich BC, Myers RP, Zincke H, Blute ML, 2005. PSA Doubling Time is an Important Predictor of Outcomes in Patients with Hormone Refractory Recurrence Following Radical Prostatectomy. *J Urol* **173(s4)**: 225 (A830)
19. **Sengupta S**, Slezak JM, Bergstralh EJ, Leibovich BC, Myers RP, Zincke H, Blute ML, 2005. Trends in Gleason Grading in Radical Prostatectomy Specimens over Time. *J Urol* **173(s4)**: 74 (A268)
20. Thompson H, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, **Sengupta S**, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED, 2005. Costimulatory B7-H1 in Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target. *J Urol* **173(s4)**: 169 (A618)
21. **Sengupta S**, Russell JM, Macgregor RJ and Duncan HJ, 2003. Audit of a Mobile Regional ESWL Service. *ANZ J Surg* **73**: A148
22. **Sengupta S**, Wong CSM, Tjandra JJ and Gibson PR, 2001. Proof that Butyrate Delivery to the Distal Colon Suppresses Colorectal Tumorigenesis in Rats. *Journal of Gastroenterol Hepatol* **16(s1)**: A21

23. **Sengupta S**, Tjandra JJ and Gibson PR, 2001. Dose-Dependent Effect of Luminal Butyrate on Epithelial Proliferation in the Distal Colon of Rats. *Journal of Gastroenterol Hepatol* **16(s1)**: A11
24. Tjandra JJ, **Sengupta S** and Gibson P, 2001. Dietary Fiber and Colorectal Neoplasia: What is the Evidence? *Dis Colon Rectum* **44**: A31
25. Tjandra JJ, **Sengupta S**, Han W, Dwyer P and Carey M, 2001. Transanal Repair of Rectocele: Four Years on. *Dis Colon Rectum* **44**: A56
26. **Sengupta S** and Tjandra JJ, 2000. Transanal Repair of Rectocele: 3 Years on. *Aust NZ J Surg* **70(s)**: A60
27. **Sengupta S**, Wong CSM, Gibson PR and Tjandra JJ, 2000. Luminal Factors that Influence Early Events in Colonic Tumourigenesis. *Aust NZ J Surg* **70(s)**: A63
28. **Sengupta S**, Webb DR, Vincent JM, and Donnellan S, 1998. CT Analysis of Calyceal Orientation in the Supine and Prone Positions. *Aust NZ J Surg* **68**: A118